Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The role of percutaneous, transhepatic management of biliary tract malignancies is to provide diagnostic and palliative care for improving patient quality of life. To treat and manage biliary tract malignancies successfully, particularly in patients who have inoperable disease, percutaneous interventions, such as biliary decompression and catheter-directed liver therapies, must be available. Although most vascular interventions do not yet commonly produce significant increased survivability in patients who have biliary tract malignancies, continued advances in percutaneous technologies suggest that future benefits in life expectancy may be achieved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2008.12.002 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!